Healthcare sector company Third Harmonic posted a -0.9% performance today, while the S&P 500 returned 0.1%.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. The company is based in Cambridge and has 22 full time employees. Its market capitalization is $170,693,609.54666138.
3 analysts are following Third Harmonic and have set target prices ranging from $3.6 to $39 per share. On average, they have given the company a rating of buy. At today's prices, THRD is trading -73.47% away from its average analyst target price of $15.87 per share.
Over the last year, THRD shares have gone down by -75.0%, which represents a difference of -66.6% when compared to the S&P 500. The stock's 52 week high is $24.59 per share and its 52 week low is $3.89. Third Harmonic has averaged free cash flows of $-12,466,500.0 over the last four years, with a mean growth rate of -71.4%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
Date Reported | Cash Flow from Operations ($ MM) | Capital expenditures ($ MM) | Free Cash Flow ($ MM) | YoY Growth (%) |
---|---|---|---|---|
2021-12-31 | -16 | n/a | -16 | -71.39 |
2020-12-31 | -9 | n/a | -9 | n/a |